Terry Gernsheimer
Overview
Explore the profile of Terry Gernsheimer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2855
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taneja S, Heddle N, Hillis C, Lane S, Karunakaran M, Maze D, et al.
Transfus Med
. 2024 Jul;
34(4):268-277.
PMID: 39032121
Background: Bleeding is a primary outcome for many transfusion-related trials in acute leukaemia (AL) patients, typically graded using the World Health Organisation (WHO) bleeding scale (clinically significant bleed (CSB) is...
2.
Boothby A, Tanner M, Alswied A, Youngs D, Bribiesca Rodriguez J, Bikkani T, et al.
Blood Adv
. 2024 Jul;
8(17):4689-4699.
PMID: 39028936
Up to a third of patients with hemato-oncologic conditions who have received multiply transfusions develop immune-mediated platelet transfusion refractoriness. Yet factors that influence posttransfusion platelet corrected count increments (CCI) in...
3.
Kuter D, Mayer J, Efraim M, Bogdanov L, Baker R, Kaplan Z, et al.
Blood Adv
. 2024 Feb;
8(7):1715-1724.
PMID: 38386978
Immune thrombocytopenia (ITP) is an autoimmune disease associated with autoantibody-mediated platelet destruction and impaired platelet production, resulting in thrombocytopenia and a predisposition to bleeding. The ongoing, global phase 1/2 study...
4.
Kuter D, Bussel J, Ghanima W, Cooper N, Gernsheimer T, Lambert M, et al.
Ther Adv Hematol
. 2023 Oct;
14:20406207231205431.
PMID: 37869360
Background: Immune thrombocytopenia (ITP) is characterized by primarily autoantibody-mediated platelet destruction and impaired platelet production resulting in thrombocytopenia and an increased risk of bleeding. Other manifestations include increased risk of...
5.
Jiang D, Rosenlind K, Baxter S, Gernsheimer T, Gulsuner S, Allenspach E, et al.
Blood Adv
. 2023 Oct;
7(23):7202-7208.
PMID: 37792884
Inborn errors of immunity (IEIs) are monogenic disorders that predispose patients to immune dysregulation, autoimmunity, and infection. Autoimmune cytopenias, such as immune thrombocytopenia (ITP) and Evans syndrome (a combination of...
6.
Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Bernheisel C, et al.
Res Pract Thromb Haemost
. 2023 May;
7(3):100134.
PMID: 37193124
No abstract available.
7.
Jain S, Gernsheimer T, Kolodny S, Bernheisel C, Vredenburg M, Panch S
Platelets
. 2023 Apr;
34(1):2195016.
PMID: 37013676
Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA) that was approved in the US in 2019 for treatment of chronic immune thrombocytopenia (ITP). This post hoc analysis of the pivotal...
8.
Kuter D, Efraim M, Mayer J, Trneny M, McDonald V, Bird R, et al.
N Engl J Med
. 2022 Apr;
386(15):1421-1431.
PMID: 35417637
Background: Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ...
9.
Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, et al.
Br J Haematol
. 2022 Feb;
197(3):359-366.
PMID: 35179784
Patients with immune thrombocytopenia (ITP) may respond to one thrombopoietin receptor agonist (TPO-RA) but not another. Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag...
10.
Appelbaum J, Arnold D, Kelton J, Gernsheimer T, Jevtic S, Ivetic N, et al.
Blood Adv
. 2021 Nov;
6(7):2250-2253.
PMID: 34724709
No abstract available.